- Home
- OTLK vs DVLT Comparison
OTLK vs DVLT Comparison
Compare OTLK & DVLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- DVLT
- Stock Information
- Founded
- OTLK 2010
- DVLT 2010
- Country
- OTLK United States
- DVLT United States
- Employees
- OTLK N/A
- DVLT N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- DVLT
- Sector
- OTLK Health Care
- DVLT
- Exchange
- OTLK Nasdaq
- DVLT NYSE
- Market Cap
- OTLK 48.3M
- DVLT 55.7M
- IPO Year
- OTLK 2016
- DVLT N/A
- Fundamental
- Price
- OTLK $1.71
- DVLT $0.72
- Analyst Decision
- OTLK Strong Buy
- DVLT Strong Buy
- Analyst Count
- OTLK 5
- DVLT 1
- Target Price
- OTLK $9.60
- DVLT $3.00
- AVG Volume (30 Days)
- OTLK 823.9K
- DVLT 445.5K
- Earning Date
- OTLK 08-13-2025
- DVLT 08-13-2025
- Dividend Yield
- OTLK N/A
- DVLT N/A
- EPS Growth
- OTLK N/A
- DVLT N/A
- EPS
- OTLK 0.83
- DVLT N/A
- Revenue
- OTLK N/A
- DVLT $3,048,000.00
- Revenue This Year
- OTLK N/A
- DVLT $434.03
- Revenue Next Year
- OTLK $379.84
- DVLT $221.43
- P/E Ratio
- OTLK $2.06
- DVLT N/A
- Revenue Growth
- OTLK N/A
- DVLT 63.08
- 52 Week Low
- OTLK $0.87
- DVLT $0.60
- 52 Week High
- OTLK $9.25
- DVLT $3.34
- Technical
- Relative Strength Index (RSI)
- OTLK 46.49
- DVLT N/A
- Support Level
- OTLK $1.65
- DVLT N/A
- Resistance Level
- OTLK $1.97
- DVLT N/A
- Average True Range (ATR)
- OTLK 0.12
- DVLT 0.00
- MACD
- OTLK -0.03
- DVLT 0.00
- Stochastic Oscillator
- OTLK 10.94
- DVLT 0.00
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About DVLT DATAVAULT AI INC
Datavault AI Inc is a data technology and licensing company that enables clients and strategic partners to monetize their Blockchain Data and AI Web 3.0 assets via tokenization, data ownership and digital twins offering two solutions: Data Science licenses High-Performance Computing (HPC) software applications and Web 3.0 data management serving the biotech, energy, education, fintech, real estate, and healthcare industries, among others. Acoustic Science licenses spatial and multichannel HD sound transmission, including proprietary brands ADIO, WiSA and Sumerian, to customers in sports & entertainment, events & venues, restaurants, automotive, finance, and other industries.